

Nigeria Support for Measles Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	Nigeria
	OUGITH V.	TRIGOTIA

- 2. **Grant number**: 1718-NGA-36a-X / 1921-NGA-09b-X / 19-NGA-36a-X/ 1920-NGA-08n-Y/ 19-NGA-37a-Y
- 3. Date of Decision Letter: 21 March 2019
- 4. Date of the Partnership Framework Agreement: 9 January 2014
- **5. Programme title:** New Vaccine Support (NVS), Measles routine 1st and 2nd dose & Measles follow-up campaign and operational costs
- 6. Vaccine type: Measles
- 7. Requested product presentation and formulation of vaccine: Measles, 10 dose(s) per vial, LYOPHILISED
- 8. Programme duration¹: 2019 2021
- **9. Programme Budget (indicative):** (subject to the terms of the partnership framework agreement, if applicable)

	History	2019	2020	2021	Total ²
Programme Budget - Routine (US\$)		US\$2,591,500	US\$1,858,500	US\$1,933,500	US\$6,383,500
Programme Budget – Campaign	US\$11,159,958	US\$7,747,500			US\$18,907,458
TOTAL	US\$11,159,958	US\$10,339,000	US\$1,858,500	US\$1,933,500	US\$25,290,958

10. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)³

Type of supplies to be purchased with Gavi funds in each year (Routine)	2019	2020
Number of vaccines doses	7,570,900	5,429,400
Annual Amounts (US\$)	US\$2,591,500	US\$1,858,500

Type of supplies to be purchased with Gavi funds in each year (Campaign)	2019
Number of vaccines doses	23,459,200

¹ This is the entire duration of the Programme.

³ This is the amount that Gavi has approved.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.



ı		
	Annual Amounts (US\$)	US\$7,747,500

- **11. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 12. Self-procurement: Not applicable
- 13. Co-financing obligations for routine: Reference code: 1921-NGA-09b-X-C

According to the co-financing policy, the Country falls within the Accelerated Transition group. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	8,150,800	8,498,000	12,999,900
Number of AD syringes	6,809,000	7,073,400	11,593,000
Number of re-constitution syringes	896,600	934,800	1,430,000
Number of safety boxes	84,775	88,100	143,275
Value of vaccine doses (US\$)	US\$2,591,931	US\$2,702,345	4,133,955
Total co-financing payments (US\$) (including freight)	US\$3,144,500	US\$3,277,500	US\$5,048,500
Minimum number of doses to be financed from domestic resources	10,716,636	8,628,000	9,382,997
Minimum amount to be financed from domestic resources (US\$)	US\$3,279,291	US\$2,640,168	US\$2,871,197

14. Co-financing obligations for campaign: Reference code: 19-NGA-36a-X-C The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019
Number of vaccine doses	1,234,700
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$377,816
Total co-financing payments (US\$) (including freight)	US\$408,000

15. Vaccine introduction grant (in US\$): Payable up to six months before vaccine introduction.

	2019	2020
Historical VIG	US\$1,680,004	US\$2,344,336

16. Operational support for campaigns: The support for operational costs for campaign will be disbursed in cash through WHO and UNICEF. The Country will need to work with WHO and UNICEF country offices and Gavi Secretariat to agree on the workplan and budget for the utilisation of GAVI funds to support the operational costs of the campaign. Payable up to six months before campaign.

	2019
Grant amount (US\$)	US\$9,696,253

17. Additional reporting requirements:



Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

	Due dates
 To prepare for the annual procurement of vaccines, Country shall submit the following information each year: vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool
To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign	Within 3 months of end of campaign
To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign	As soon as available

- 18. Financial clarifications: Not applicable
- 19. Other conditions: As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Signed by,

On behalf of Gavi

Hind Khatib-Othman Managing Director, Country Programmes

Lilate H. Shill

21 March 2019